Group 1 - The presentation focuses on the Phase III ALLEGORY results for Gazyva in systemic lupus erythematosus (SLE), which were recently presented at SLEuro [2] - The agenda includes updates on the pipeline in immune-mediated kidney and rheumatological diseases, specifically mentioning the Gazyva development program and other B-cell depleting agents in development [3]